Advertisement
Singapore markets close in 6 hours 33 minutes

  • Straits Times Index

    3,290.47
    +2.72 (+0.08%)
     

  • Nikkei

    37,801.79
    +173.31 (+0.46%)
     

  • Hang Seng

    17,566.14
    +281.60 (+1.63%)
     

  • FTSE 100

    8,078.86
    +38.48 (+0.48%)
     

  • Bitcoin USD

    64,509.45
    +235.28 (+0.37%)
     

  • CMC Crypto 200

    1,389.49
    +6.92 (+0.50%)
     

  • S&P 500

    5,048.42
    -23.21 (-0.46%)
     

  • Dow

    38,085.80
    -375.12 (-0.98%)
     

  • Nasdaq

    15,611.76
    -100.99 (-0.64%)
     

  • Gold

    2,347.50
    +5.00 (+0.21%)
     

  • Crude Oil

    83.83
    +0.26 (+0.31%)
     

  • 10-Yr Bond

    4.7060
    +0.0540 (+1.16%)
     

  • FTSE Bursa Malaysia

    1,572.36
    +3.11 (+0.20%)
     

  • Jakarta Composite Index

    7,121.22
    -34.07 (-0.48%)
     

  • PSE Index

    6,570.20
    -4.68 (-0.07%)
     

Analysts’ Recommendations for Exelixis in April 2018

Daniel Collins
Updated
Analysts’ Recommendations for Exelixis in April 2018

In February 2018, Exelixis (EXEL) and its partner Daiichi Sankyo announced that it had submitted a regulatory application for esaxerenone therapy to the Japanese Pharmaceutical and Medical Devices Agency for the treatment of individuals with hypertension. According to the prior agreement between Exelixis and Daiichi Sankyo, Exelixis is set to receive a milestone payment of $20 million from Daiichi Sankyo. Daiichi Sankyo’s regulatory application has been supported by the results of Phase 3 trials evaluating the safety and efficacy of esaxerenone in individuals with essential hypertension compared to eplerenone.

Continue reading